Nos­trum agrees to $50M set­tle­ment with DOJ over al­le­ga­tions of un­der­pay­ing Med­ic­aid

Mis­souri-based phar­ma Nos­trum Lab­o­ra­to­ries and its CEO have agreed to pay a min­i­mum $3.8 mil­lion and up to $50 mil­lion to set­tle ac­cu­sa­tions from the US De­part­ment of Jus­tice that the com­pa­ny vi­o­lat­ed the False Claims Act.

Ac­cord­ing to the DOJ, Nos­trum and its CEO were “know­ing­ly un­der­pay­ing Med­ic­aid re­bates due for Nos­trum’s drug Ni­tro­fu­ran­toin Oral Sus­pen­sion” af­ter hik­ing up the price of the an­tibi­ot­ic. The set­tle­ment could go up to $50 mil­lion if cer­tain fi­nan­cial con­tin­gen­cies are met, though the de­part­ment did not spec­i­fy the con­tin­gen­cies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER